Social factors, blood markers and mood symptoms in brain diseases and mental disorders
Studies how social factors and blood markers relate to psychiatric symptoms in adults.
Plain-language title generated from the registry record
Registry title: Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- IRSPBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07239843
- Record updated
- 24 April 2026
- Original description
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for psychiatric symptoms with biological changes in patients suffering from a mental disorder (MD) or a neurodegenerative disease (ND).Read full original descriptionShow less
Synapsing's Multinational Sociodemographic Study
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for psychiatric symptoms with biological changes in patients suffering from a mental disorder (MD) or a neurodegenerative disease (ND).
Inclusion: Age>18 and donation of blood,; full clinical and psychological assessment; Available neuroimaging is optional as not all patients are suitable; Age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls; Unaffected controls are usually spouses or children of patients that are informed about our studies at each clinical site.
Exclusion: anticoagulant treatment such as acenocoumarol, heparin, warfarin, dabigatran, rivaroxaban, apixaban, drug abuse in the last year,; the patient has received potentially neurotoxic chemotherapy and/or patient has received cranial radiotherapy; medical history of cancer affecting the central nervous system that has not been in complete remission for 5 years or longer,; Clinical diagnosis of Alzheimer's disease where pathophysiological markers (measured in CSF or plasma) are inconsistent with Alzheimer's disease pathophysiology; Cognitively healthy volunteers where pathophysiological markers (measured in CSF or plasma) are consistent with Alzheimer's disease or other neurodegenerative pathophysiology; Lack of neuropsychological data,.